NCT04584892 - Turoctocog Alfa in Haemophilic Italian Patients: Protection and Engagement in Recreational Activities | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 12, 2021

Primary Completion Date

March 27, 2023

Study Completion Date

March 27, 2023

Conditions

Haemophilia A

Interventions

DRUG

Turoctocog alfa

Patients will be treated with commercially available NovoEight® (turoctocog alfa) according to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available NovoEight® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.

Trial Locations (10)

20089

Novo Nordisk Investigational Site, Milan

20124

Novo Nordisk Investigational Site, Milan

31033

Novo Nordisk Investigational Site, Castelfranco Veneto

36100

Novo Nordisk Investigational Site, Vicenza

40138

Novo Nordisk Investigational Site, Bologna

47521

Novo Nordisk Investigational Site, Cesena

50134

Novo Nordisk Investigational Site, Florence

80147

Novo Nordisk Investigational Site, Napoli

95123

Novo Nordisk Investigational Site, Catania

00161

Novo Nordisk Investigational Site, Roma